Condition: Pneumococcal Disease · Sponsor: Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
This description comes directly from the study's public registry record.
Xuecheng LIU · +86 189 8195 8206 · 534210793@qq.com
Always discuss trial participation with your own doctor first.
| Sichuan Center For Disease Control and Prevention | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06044077